Jobs / United States / Glaxosmithkline LLC
CMC Report Transformation Senior Director
Glaxosmithkline LLC · 🇺🇸 5 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles4 certified filings for “Associate Director – Genomic Technologies” (Molecular and Cellular Biologists) in PA: $134k–$138k, median $136k. Most were filed at wage level IV (50%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
Job Title: CMC Report Transformation Senior Director Job Purpose To provide strategic oversight and long-range planning for the portfolio of Report Transformation tools and strategies within CMC (Chemistry, Manufacturing and Controls), defining the vision, strategy, and roadmap that determine how capabilities are prioritised, resourced, delivered, and scaled across the function. This role takes the Drug Development and Supply (DDS) lead role for the SONATA (GSK’s automated and digital regulatory report creation) programme and acts as representation and decision maker on all senior governance forums as well as orchestrating the delivery required on a more local level. In addition, the role is accountable for the transformation of all technical report writing across DDS and for the realisation of benefits of implemented tools and reimagined reporting. The role is ultimately accountable for determining and realising the value of report transformation within the regulated CMC environment, ensuring solutions are scientifically robust, responsibly governed, and demonstrably impactful. Key Responsibilities: • Provide strategic oversight and long-range planning for the report transformation product portfolio within CMC, setting direction that aligns autonomous capabilities with functional and enterprise priorities. • Define and own the product roadmap for report transformation within CMC, sequencing investment and delivery to maximise scientific and business value over the short, medium, and long term. • Lead enterprise-level prioritisation across competing demands, making transparent, evidence-based trade-offs to focus resources on the highest-value report transformation opportunities. • Hold end-to-end technical accountability for report transformation strategy and products, ensuring solutions are architecturally sound, performant, validated, and fit for use in a regulated CMC setting. • Hold full accountability for the people, budget, and delivery resources needed to execute the portfolio, including senior recruitment and organisational design decisions, spanning internal teams and external technology partners. • Lead complex, multi-level stakeholder management across the scientific, technical, quality, and senior leadership communities, building alignment and securing sponsorship for agentic AI initiatives. • Determine, measure, and articulate the value of report transformation products, defining success metrics and demonstrating quantifiable scientific, operational, and commercial impact. • Manage complex stakeholders across DDS, Regulatory, Digital & Tech and Quality organisations to ensure compliant but transformative decisions are made. • Build, lead, and develop a high-performing team of product and technical leaders, embedding coaching, talent development, and succession planning across the report transformation portfolio. • Act as the senior executive sponsor for report transformation within CMC, representing the function at VP and senior leadership forums and shaping enterprise-wide digital and AI strategy. Basic Qualifications: • Bachelor's degree in Computer Science, Data Science, Engineering, Life Sciences, Regulatory Affairs, or a closely related scientific or technical field. • Experience in product management and product leadership, delivering data, software, and AI/ML products • Experience operating at director level or above, and substantial experience setting enterprise strategy for and delivering complex, production-grade AI products ideally including agentic or autonomous AI within a scientific, healthcare, or pharmaceutical (CMC) environment, including direct experience transforming regulatory or technical report writing and documentation processes through automation, digital tooling, o